To study the efficacy of benfothiamine in treating patients with diabetic polyneuropathy (DPN) in its various stages of manifestation. Methods. The first stage of the study involved 45 patients with positive Diabetic Neuropathy Symptom (DNS) score, 28 females, 17 males with type 2 diabetes and average duration of diabetes 7-10 years. All the participants were assessed before the commencement of therapy (benfothiamine 300 mg) and after 6 weeks of therapy. Participants were assessed using the DNS score, biothesiometer, monofilament test. CBC, kidney profile, LFT, glycosylated haemoglobin were measured in all the subjects. All patients were questioned regarding the presence or otherwise of symptoms, either positive or negative indicating the presence of neuropathy. The questionnaire used was the DNS score. The score is based upon the regular occurrence of four different symptoms of distal sensory polyneuropathy, including tingling, burning, numbness and unsteadiness of gait. The score has a range of 0-4, and a score of ≥1 is considered indicative of DSPN. Results. The DNS score in 19 females decreased from +4 to +2 whereas in the male group in 12 patients the DNS score decreased from +4 to +2.5. Out of the 28 females 14 had moderate sensory loss on the biothesiometer with voltage ranging between 18-24 volts, 2 patients had severe sensory loss with voltage 38-40, and 12 patients had mild sensory loss with voltage between 17-25. In the male group, 10 patients had moderate sensory loss with voltage ranging between 26-34 volts, 5 patients had mild sensory loss with voltage between 15-22 volts, and 2 patients had normal values. Upon completion of the 6 week period on benfothiamine therapy the threshold of sensory loss decreased by 5-8% in the patients with moderate loss. Conclusion. The significance of benfothiamine in clinical practice has also been demonstrated in many clinical trials with variable trial structures, patient groups and history of diabetes. In the first stage of our study we found that patients with moderate sensory loss were the ones who benefitted the most from benfothiamine therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.